1. Pfizer's acquisition of Seagen enhances its ADC technology, potentially expanding its oncology franchise and driving future growth; 2. PFE's development of the oral GLP-1 receptor agonist, Danuglipron, aims to capture the growing obesity and diabetes treatment market by 2028; 3. The Company anticipates 11.4% revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization, despite challenges from declining COVID-related revenue.

1. Janux Therapeutics, a clinical-stage biotech company, has seen its stock rise significantly in 2024 due to buyout speculation and promising early-stage trial data. 2. The company focuses on developing oncology therapies using its proprietary Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms. 3. Despite a robust balance sheet and potential large markets, the company's pipeline is early-stage, and there has been significant insider selling.